2013
DOI: 10.5858/arpa.2012-0445-oa
|View full text |Cite
|
Sign up to set email alerts
|

Histologic and Immunohistochemical Analyses of Endometrial Carcinomas: Experiences From Endometrial Biopsies in 358 Consultation Cases

Abstract: Context.-Uterine serous carcinoma is biologically more aggressive than the endometrioid carcinoma. Because uterine serous carcinoma has a high propensity for lymphovascular invasion and intraperitoneal and extraabdominal spread, accurate diagnosis of this tumor type in endometrial biopsies/curettings is critical for appropriate clinical management.Objective.-To share our experience in the evaluation of endometrial biopsy specimens in type I and type II endometrial adenocarcinoma.Design.-We retrospectively revi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
13
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 37 publications
(15 citation statements)
references
References 22 publications
(25 reference statements)
1
13
0
Order By: Relevance
“…These rare tumour types are biologically distinct from the more common endometrioid carcinoma and generally carry a worse prognosis. Endometrial serous carcinoma is recognised with a higher propensity to lympho-vascular invasion and spread [116]. Endometrioid cancer is linked to alterations in PTEN gene silencing, defects in DNA mismatch repair genes, microsatellite instability and mutations in KRAS and of β-catenin.…”
Section: Resultsmentioning
confidence: 99%
“…These rare tumour types are biologically distinct from the more common endometrioid carcinoma and generally carry a worse prognosis. Endometrial serous carcinoma is recognised with a higher propensity to lympho-vascular invasion and spread [116]. Endometrioid cancer is linked to alterations in PTEN gene silencing, defects in DNA mismatch repair genes, microsatellite instability and mutations in KRAS and of β-catenin.…”
Section: Resultsmentioning
confidence: 99%
“…[19][20][21] Mutational assays that can help include p53, PTEN, phosphoinositide 3-kinase (PIK3) catalytic subunit α (PIK3CA), PIK3 regulatory subunit 1 (PIK3R1), fibroblast growth factor receptor 2 (FGFR2), ARID1A, catenin β1 (CTNNB1), Kirsten rat sarcoma viral oncogene homolog (KR AS), and protein phosphatase 2 scaffold subunit Aα (PPP2R1A). No single marker is sensitive and specific enough to reliably define a histotype 22 and, although numerous panels have been proposed that improve histologic interobserver agreement, the specific elements of such a panel are not universally agreed upon.…”
Section: Prognostic Factorsmentioning
confidence: 99%
“…The mortality was higher for patients with type II rather than patients with type I (5) because type I cancers are more likely to grow and spread outside the uterus. However, this type is only presented in 20% of all endometrial cancer cases, which consists of less common histological subtypes such as serous carcinoma, clear cell carcinoma and carcinosarcoma (6). Although endometrioid types are more common in endometrial cancer patients (80%-85% of all cases) (6), they are not outcome factor was survival time, defined as the time to death of patients due to endometrial cancer or its complications.…”
Section: Introductionmentioning
confidence: 99%